IP Library › Patent Application 19403633
Patent Application
App. No. 19/403,633

Compositions and Methods for Treating Cardiovascular Diseases and Disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/403,633
Abstract

Disclosed herein are compounds and ligands, and compositions formed therewith, that treat insulin resistance-induced physiological disorders by modulating G-protein coupled receptor (GPCR) and transient receptor potential (TRP) ion channel activity. Also disclosed herein are methods for using the compositions to treat cardiovascular disorders, such as atherosclerosis.

Claims (15)

1 . A method for treating atherosclerosis presented by a subject, comprising the steps of:

providing a composition comprising a delivery medium, at least a first receptor activating compound, at least a second receptor activating compound and a receptor antagonizing compound,

said first receptor activating compound comprising butyl butyryl lactate, said butyl butyryl lactate comprising in the range of approximately 3.0% to approximately 5.0% (w/w) of said composition,

said second receptor activating compound comprising lauric acid, said lauric acid comprising in the range of approximately 0.1% to approximately 0.5% (w/w) of said composition,

said receptor antagonizing compound comprising 3,3′,4′,5,6,7,8-heptamethoxyflavone (HMF), said HMF comprising in the range of approximately 15.0% to approximately 17.0% (w/w) of said composition,

said composition adapted to induce activation of at least olfactory receptor family 51 subfamily E member 1 (OR51E1) and free fatty acid receptor 1 (FFAR1) activity in vivo, and induce abatement of 5-HT 2 -serotonin receptor activity in vivo; and

delivering said composition to said subject, wherein secretion of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) is induced, and atherosclerotic platelet aggregation is abated.

2 . The method of claim 1 , wherein said butyl butyryl lactate comprises at least 3.0% (w/w) of said composition.

3 . The method of claim 1 , wherein said lauric acid comprises at least 0.1% (w/w) of said composition.

4 . The method of claim 1 , wherein said HMF comprises at least 15.0% (w/w) of said composition.

5 . The method of claim 1 , wherein said composition further comprises a third receptor activating compound comprising eugenol, said eugenol comprising at least 3.0% (w/w) of said composition.

6 . The method of claim 1 , wherein said composition further comprises a fourth receptor activating compound comprising cinnamaldehyde, said cinnamaldehyde comprising at least 24.0% (w/w) of said composition.

7 . The method of claim 1 , wherein said composition further comprises a fifth receptor activating compound comprising benzyl acetate, said benzyl acetate comprising at least 0.5% (w/w) of said composition.

8 . The method of claim 1 , wherein said composition further comprises a sixth receptor activating compound comprising spearmint oil, said spearmint oil comprises at least 7.0% (w/w) of said composition.

9 . The method of claim 1 , wherein said delivery medium comprises sunflower seed oil.